VJVirtual | INVICTUS: long-term results for ripritnanib as 4th-line therapy in advanced GIST

Robin Jones, MD, The Royal Marsden Hospital, London, UK, shares the long-term analysis of the Phase III INVICTUS (NCT03353753) trial investigating ripretinib in advanced gastrointestinal stromal tumor (GIST). The results showed a continued benefit of ripretinib in this patient population in regards to the primary endpoint, progression-free survival (PFS). The PFS rate at 6 months was 51% for patients receiving ripretinib versus 3.2% for patients receiving placebo and the 12 months PFS rate was 22.2% for ripretinib and not evaluable (NE) for placebo. At 18 months, the PFS rate was 11.8% in the ripretinib arm. The overall response rate (ORR) was 12% versus 0% for ripretinib versus placebo and overall-survival (OS) at 24 months was 42.8% compared to 19% for ripretinib and placebo, respectively. The long-term analysis of the INVICTUS trial confirmed the use of ripretinib in the fourth-line setting for the treatment of advanced GIST.